- |||||||||| Strensiq (asfotase alfa) / AstraZeneca, Prolia (denosumab) / Amgen
Adult-Onset Hypophosphatasia with Atypical Femoral Fractures: A Diagnostic and Management Challenge (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_1732;
Persistently low ALP, atypical fractures, and genetic confirmation are key diagnostic markers. This case underscores the need for clinical awareness and early intervention, as asfotase alfa may play a crucial role in improving skeletal outcomes in adults with progressive disease.
- |||||||||| maridebart cafraglutide (AMG 133) / Amgen, Mounjaro (tirzepatide) / Eli Lilly
A comparison of the metabolic effects of a long-acting GIPR agonist versus a GIPR antagonist (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_1669;
Moreover, the observation that GIP108 was unable to prevent GLP-1RA induced emesis, an effect induced by other GIPR agonists, highlights the heterogeneity in CNS responses induced by different GIPR agonists. A comparison of the metabolic effectiveness of both approaches in humans is an important area of future study.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Rapid Progression of New Onset Diabetes after starting Tepezza for Thyroid Eye Disease (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_1593;
Patients with pre-diabetes that are started on Tepezza infusions need to be closely monitored for development of diabetes so that appropriate therapy can be initiated. Once infusions are completed, patients need to be monitored for rapid improvement in diabetes and de-escalation of treatment.
- |||||||||| Prolia (denosumab) / Amgen, Cresemba (isavuconazonium sulfate) / Astellas, Basilea
An Unusual Presentation of Histoplasmosis: Bilateral Adrenal Masses and Hypercalcemia (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_1474;
It also underscores the diagnostic interplay between hypercalcemia and adrenal pathology, where both malignancy and infectious etiologies can present with overlapping features. Early identification and targeted investigations are crucial to distinguish between these conditions, ensuring timely and appropriate management.
- |||||||||| Prolia (denosumab) / Amgen
Mortality and Hospitalization Outcomes in Patients Aged 80 and Older Receiving Osteoporosis Treatment After Fracture (Room 153) - Apr 27, 2025 - Abstract #ENDO2025ENDO_889;
Outcomes included occurrence of hospitalization within 5 years and death within 5 years. The analysis showed that patients who suffered an osteoporotic fracture at age 80 years old or later and received subsequent osteoporosis treatment (Cohort 1) had lower incidence of hospitalizations (18,142 vs 20,385 patients, with an odds ratio of 0.814 and 95% CI 0.792,0.836), and experienced lower all-cause mortality (11,073 vs 12,479 patients, OR 0.850, 95% CI 0.825, 0.876).The data obtained in this large U.S study suggests that, among patients with osteoporosis who suffer a fragility fracture at age 80 years old or later, those who receive treatment for osteoporosis have a lower incidence of all-cause mortality and lower incidence of hospitalizations in the 5-year follow-up period, supporting the initiation of osteoporosis treatment in this elderly population.
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Bone Gains and Heart Strains: Romosozumab and Cardiovascular Safety (Room 153) - Apr 27, 2025 - Abstract #ENDO2025ENDO_884;
These findings suggest there is no heightened risk for major adverse cardiovascular events in patients with osteoporosis treated with romosozumab compared to anabolic agents (teriparatide or abaloparatide). Further observational data is required to concur such findings, which may lead to a discontinuation of the black-box warning.
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab Increases Spine and Hip Bone Mineral Density in Women With Anorexia Nervosa (Room 153) - Apr 27, 2025 - Abstract #ENDO2025ENDO_883;
Romosozumab was well tolerated. In conclusion, in this pilot, randomized, placebo-controlled study, 12 months of therapy with romosozumab markedly increased spine and hip BMD in women with anorexia nervosa, increasing BMD Z-score to >-1 in a significant number of women.
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Significant One-Year Bone Mineral Density Gains Following a Single Dose of Romosozumab: Insights from Two Case Studies (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_784;
Between August 2023 and September 2024, she had statistically significant improvements in BMD at the lumbar spine (13.9%), right femur (7.9%), and left femur (9.6%).Patient 2 is a 67 year old female with osteoporosis treated with one dose of Romosozumab in January 2024 followed by one dose of Zoledronic acid in February 2024...Our patients' one-year BMD improvement after one dose of Romosozumab was similar to the one-year BMD improvement of clinical trial patients after twelve doses of Romosozumab. 2.There is a need for further research to determine whether shorter treatment courses could reduce fractures effectively, minimize side effects, and lower the cost of osteoporosis care.
- |||||||||| Prolia (denosumab) / Amgen
The Role of Full Femur Imaging for Early Detection of Incomplete Atypical Femur Fractures (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_783;
Title: The Role of Full Femur Imaging for Early Detection of Incomplete Atypical Femur Fractures Introduction: Atypical femur fractures (AFFs) are a rare but serious complication linked to prolonged use of bisphosphonates and denosumab...After seven years on alendronate, she sustained a complete right AFF requiring intramedullary nailing...Incorporating FFI into routine osteoporosis care is not routinely implemented and may highlight a gap in current practice. This case emphasizes the need for clear guidelines on screening for AFFs and the potential role of FFI in personalized imaging protocols to enhance patient care.
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Use of Romosozumab for Osteoporosis in ?-Thalassemia Major (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_780;
There are currently no reports examining the efficacy of the anabolic Romosozumab in TM.We report the use of Romosozumab in 2 patients with TM and severe osteoporosis.A 65-year-old male with TM on deferoxamine chelation, also had small vessel vasculitis requiring high doses of corticosteroids...Despite 5 years of zoledronic acid (ZA) treatment, there was ongoing decline in BMD at both lumbar spine and hip and he sustained a new L3 fracture...He tolerated Romosozumab well and is currently undergoing consolidation treatment with ZA.A 58-year-old Jehovah's Witness male with TM, osteoporosis and multiple fractures had been treated with various osteoporosis therapies over 20 years, including bisphosphonates, strontium ranelate and denosumab...The observed BMD gains were significant despite previous prolonged exposure to anti-resorptive therapy, and thus represents a promising treatment option in patients with TM and osteoporosis. A clinical trial to confirm these benefits is required.
- |||||||||| Prolia (denosumab) / Amgen
From Bone Density to Bone Death: Osteonecrosis of the Jaw in a Patient with Minimal Risk Factors (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_779;
It emphasizes the importance of careful monitoring during BP therapy, and also raises the concern about treatment options for managing worsening OP in patients with BRONJ. Non-BP therapies, such as denosumab or teriparatide, could be considered to prevent further bone loss and fractures, but also carries the risk of ONJ, although data is limited.
- |||||||||| Prolia (denosumab) / Amgen
Does Excluding Regions of Interest Affect Least Significant Change (LSC) Calculations in Trabecular Bone Score (TBS)? (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_773;
Recent recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF) suggest that TBS may be beneficial for monitoring treatment with denosumab and anabolic agents...In clinical practice, there are instances where certain regions of interest should be excluded. In line with recent ESCEO recommendations regarding treatment monitoring and TBS, we believe it is essential for each center to assess the LSC for various vertebral combinations.
- |||||||||| Prolia (denosumab) / Amgen
Primary Hyperparathyroidism in a Patient with Osteogenesis Imperfecta Type I and Osteoporosis (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_755;
She was diagnosed with osteoporosis after menopause in her early 50s and was started on risedronate...Although some treatments for osteoporosis and OI overlap, we have limited, long-term data on denosumab use...Routine measurement of calcium should be done in patients with OI as these conditions can occur and the diagnosis and opportunity for treatment can be missed. Additional studies are needed to establish this concurrence.
- |||||||||| Prolia (denosumab) / Amgen
A Case of Parathyroid Crisis with EKG Changes Mimicking ST Elevation Myocardial Infarct (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_750;
One case presented with both ST changes and elevated troponin levels, as in our patient, likely due to demand ischemia. Our case presented a particularly challenging diagnostic dilemma with the cooccurrence of ST elevation, up-trending troponins and new wall motion abnormalities on TTE, which suggested acute MI, but ultimately no culprit lesion was identified on angiography.
- |||||||||| Prolia (denosumab) / Amgen
Ectopic Parathyroid Hormone Secretion: An Unusual Cause of Severe Hypercalcemia (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_745;
The patient was treated with IV fluids, zoledronic acid, calcitonin, cinacalcet, and subsequently denosumab for refractory hypercalcemia. A significantly elevated PTH, which is usually a feature of parathyroid carcinoma, could also be due to production from a non-parathyroid malignancy.
- |||||||||| Prolia (denosumab) / Amgen
The Calcium Bandits: A Case of Combination Lanreotide and Denosumab Induced Hypocalcemia. (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_735;
This suggests that lanreotide has long term effect on calcium homeostasis, likely due to intestinal calcium malabsorption contributing to secondary hyperparathyroidism. This study shows that lanreotide decreases serum calcium enough to trigger increased PTH secretion from parathyroid glands.Lanreotide should be considered a risk factor for hypocalcemia, particularly in patients receiving denosumab.
- |||||||||| Prolia (denosumab) / Amgen
Two Cases of Denosumab-induced Hypocalcemia in patients with Bariatric surgery (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_732;
While effective in its role, denosumab can also disrupt the body's calcium homeostasis, potentially leading to hypocalcemia, especially in patients with pre-existing conditions that affect calcium metabolism. These cases underscore the importance of careful patient selection when prescribing Denosumab, particularly in those with a history of gastric bypass surgery and highlighting the importance of monitoring of serum calcium levels.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Not a Stroke: A Case of Sight Threatening Thyroid Eye Disease With Delayed Diagnosis (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_407;
Unfortunately, there can be barriers to accessing the antibody treatment. These can include a need for follow-up with a hard-to-find thyroid eye disease specialist registered with the company, lack of insurance coverage, treatment expense, and a lack of infusion center nurses trained to assess hearing.
- |||||||||| Repatha (evolocumab) / Amgen, Astellas
Breaking the Triglyceride Barrier: A Case of Severe Hypertriglyceridemia Management (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_331;
Pharmacologic therapy included continuation of rosuvastatin 40 mg, fenofibrate 160 mg, and ezetimibe 10 mg. Patient was also started on Icosapent ethyl 2 g twice daily and Levothyroxine (LTX) was increased from 125 mcg to 150 mcg due to an elevated TSH level of 10.4
- |||||||||| Evkeeza (evinacumab-dgnb) / Regeneron
Evinacumab as an Effective Treatment Option for Refractory Hypertriglyceridemia (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_327;
Evinacumab may be an effective alternative agent for the management of chronic hypertriglyceridemia based on the robust effects seen in our patient. Future research is needed to explore evinacumab's therapeutic targets beyond LDL-C to better modify risk factors for atherosclerosis, as well as CAV progression in heart transplant recipients.
- |||||||||| Praluent (alirocumab) / Sanofi, Regeneron, Leqvio (inclisiran) / Novartis, Repatha (evolocumab) / Amgen, Astellas
A Case Series of Heterozygous Familial Hypercholesteremia With PCSK9 Inhibitor Failure (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_322;
Ezetimibe 10mg daily was added and patient is awaiting approval for inclisiran.CASE 2: An 18-year-old woman with type 1 diabetes and celiac disease was seen in September 2012 for dyslipidemia...Pravastatin 40 mg was started but discontinued due to myalgias...Further research is needed to understand the underlying mechanisms and the likelihood of this occurring in other patients. These cases also highlight the need for ongoing vigilance in patients with high cholesterol and HeFH to ensure optimal cardiovascular protection.
- |||||||||| Prolia (denosumab) / Amgen
A study Of Denosumab In Children With Glucocorticoid-Induced Osteoporosis (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_298;
Conclusion Real-world evidence has shown that the incidence of children with glucocorticoid-induced osteoporosis, has reduced dramatically over time, concurrently with increased use of biological agents to treat rheumatological disease in children. In this study, treatment with denosumab showed no statistical difference in increase from baseline in lumbar spine BMD Z-score.
- |||||||||| ivabradine / Generic mfg.
Journal: Ivabradine exposures reported to United States poison centers 2015-2023. (Pubmed Central) - Apr 26, 2025
Adults with unintentional, asymptomatic exposures to ivabradine may be candidates for home monitoring. In ivabradine exposures refractory to medical management, clinicians should consider cardiac pacing or other supportive measures as a temporizing measure.
- |||||||||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Trial completion date: NCI-2011-00344: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 26, 2025
P1/2, N=8, Active, not recruiting,
Not yet recruiting --> Recruiting Trial completion date: Mar 2025 --> Feb 2026
|
